EUCTR2004-001220-20-IT进行中（未招募）不适用
Efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C genotype 1 non responder to Pegasys.
SCHERING-PLOUGH0 个研究点目标入组 200 人开始时间: 2007年2月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - Non Responder StudyEUCTR2004-001220-20-DEIntegrated Therapeutics Group, Incorporated- a subsidiary of Schering Plough200
进行中（未招募）
1 期
Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - Non-Responder StudyChronic Hepatitis C, Genotype 1EUCTR2004-001220-20-ESIntegrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough200
进行中（未招募）
1 期
Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - Non-Responder StudyChronic Hepatitis C, Genotype 1EUCTR2004-001220-20-GBIntegrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough200
进行中（未招募）
不适用
Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys - Non-Responder StudyChronic Hepatitis C, Genotype 1EUCTR2004-001220-20-ATIntegrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough200
进行中（未招募）
不适用
Study to assess treatment with PegIntron and Rebetol in naive patients with genotype 1 chronic hepatitis C and slow virological response.Chronic Hepatitis C genotype 1.MedDRA version: 9.1Level: LLTClassification code 10019744Term: Hepatitis CEUCTR2004-000488-83-ITSCHERING-PLOUGH1,200